Profile data is unavailable for this security.
About the company
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
- Revenue in EUR (TTM)37.65bn
- Net income in EUR11.22bn
- Incorporated1994
- Employees100.41k
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Kiadis Pharma NV | 8.57% | 254.17m |
| Principia Biopharma Inc | -1.71% | 3.67bn |
| Synthorx Inc | 0.53% | 2.45bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonza Group AG | 5.54bn | 779.81m | 39.05bn | 15.91k | 50.19 | 6.52 | 56.86 | 7.05 | 11.35 | 11.03 | 80.66 | 87.33 | 0.4387 | -- | -- | 389,061.30 | 6.18 | 5.23 | 7.34 | 6.51 | 38.72 | 36.17 | 14.09 | 11.13 | -- | 10.88 | 0.3685 | 33.94 | 6.82 | 10.22 | 16.34 | 26.31 | 34.29 | 3.50 |
| GlaxoSmithKline plc | 38.08bn | 7.08bn | 76.40bn | 99.44k | 10.82 | 4.81 | 9.61 | 2.01 | 1.27 | 1.27 | 6.81 | 2.85 | 0.4174 | 1.66 | 4.28 | 344,529.70 | 8.61 | 7.62 | 13.61 | 12.66 | 68.07 | 68.62 | 20.63 | 14.92 | 0.606 | 10.68 | 0.578 | 102.31 | 9.52 | 7.97 | 32.79 | 11.00 | 4.32 | 0.00 |
| Novo Nordisk A/S | 17.09bn | 5.58bn | 102.20bn | 44.33k | 23.72 | 16.21 | 16.08 | 5.98 | 17.70 | 17.70 | 54.19 | 25.88 | 0.9607 | 1.16 | 5.43 | 2,979,299.00 | 31.37 | 37.41 | 63.50 | 70.35 | 83.69 | 84.40 | 32.65 | 33.35 | 0.7831 | 20.97 | 0.0645 | 49.70 | 9.11 | 6.56 | 0.8362 | 8.02 | 20.97 | 10.80 |
| Sanofi SA | 37.65bn | 11.22bn | 106.65bn | 100.41k | 9.50 | -- | 8.43 | 2.83 | 8.92 | 8.91 | 29.97 | -- | -- | -- | -- | 374,966.40 | -- | 3.69 | -- | 4.39 | 67.66 | 68.37 | 28.83 | 10.78 | -- | 36.48 | -- | 96.70 | 5.48 | 3.30 | -32.69 | -7.41 | 4.56 | 2.02 |
| AstraZeneca plc | 21.59bn | 2.08bn | 113.79bn | 70.60k | 54.64 | 11.18 | 21.67 | 5.27 | 1.43 | 1.43 | 14.79 | 6.98 | 0.4206 | 1.51 | 4.73 | 275,086.40 | 3.93 | 3.84 | 5.59 | 5.34 | 80.09 | 81.46 | 9.34 | 10.08 | 0.7646 | 3.32 | 0.6213 | 144.62 | 10.38 | -1.69 | -38.05 | 1.60 | -2.22 | 0.6658 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Oct 2020 | 32.56m | 2.59% |
| Norges Bank Investment Managementas of 31 Dec 2019 | 26.69m | 2.12% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2020 | 20.20m | 1.60% |
| BlackRock Fund Advisorsas of 05 Nov 2020 | 16.80m | 1.33% |
| Dodge & Coxas of 30 Sep 2020 | 14.55m | 1.16% |
| Amundi Asset Management SA (Investment Management)as of 24 Nov 2020 | 13.92m | 1.11% |
| Lyxor International Asset Management SASas of 25 Nov 2020 | 13.69m | 1.09% |
| BNP Paribas Asset Management France SASas of 05 Nov 2020 | 10.38m | 0.83% |
| FIL Investment Advisors (UK) Ltd.as of 30 Sep 2020 | 9.75m | 0.78% |
| BlackRock Advisors (UK) Ltd.as of 05 Nov 2020 | 9.73m | 0.77% |
